ATE432339T1 - Verwendung von onkofötal-antigen spezifischen cd4,cd8 zytotoxischen, suppressor t-zellen und interleukin-10 - Google Patents

Verwendung von onkofötal-antigen spezifischen cd4,cd8 zytotoxischen, suppressor t-zellen und interleukin-10

Info

Publication number
ATE432339T1
ATE432339T1 AT97921106T AT97921106T ATE432339T1 AT E432339 T1 ATE432339 T1 AT E432339T1 AT 97921106 T AT97921106 T AT 97921106T AT 97921106 T AT97921106 T AT 97921106T AT E432339 T1 ATE432339 T1 AT E432339T1
Authority
AT
Austria
Prior art keywords
cells
oncofetal antigen
individual
tumor
suppressor
Prior art date
Application number
AT97921106T
Other languages
English (en)
Inventor
Joseph Coggin
Adel Barsoum
James Rohrer
Original Assignee
Univ South Alabama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Alabama filed Critical Univ South Alabama
Application granted granted Critical
Publication of ATE432339T1 publication Critical patent/ATE432339T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57476—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofetal proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97921106T 1996-04-05 1997-04-04 Verwendung von onkofötal-antigen spezifischen cd4,cd8 zytotoxischen, suppressor t-zellen und interleukin-10 ATE432339T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1490396P 1996-04-05 1996-04-05
PCT/US1997/005685 WO1997038089A1 (en) 1996-04-05 1997-04-04 Uses of oncofetal antigen specific cd4, cd8 cytotoxic and suppressor t cells and interleukin-10

Publications (1)

Publication Number Publication Date
ATE432339T1 true ATE432339T1 (de) 2009-06-15

Family

ID=21768461

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97921106T ATE432339T1 (de) 1996-04-05 1997-04-04 Verwendung von onkofötal-antigen spezifischen cd4,cd8 zytotoxischen, suppressor t-zellen und interleukin-10

Country Status (7)

Country Link
US (2) US6335174B1 (de)
EP (1) EP0939796B1 (de)
AT (1) ATE432339T1 (de)
AU (1) AU2723597A (de)
CA (1) CA2250164C (de)
DE (1) DE69739423D1 (de)
WO (1) WO1997038089A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003258081A1 (en) * 2002-08-02 2004-02-23 South Alabama Medical Sciences Foundation Cancer vaccines containing epitopes of oncofetal antigen
EP1444989A1 (de) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisierung von Zellen für die Apoptose durch selektive Blockade von Zytokinen
CN102112491A (zh) * 2008-06-06 2011-06-29 贝勒研究院 抗-cd8抗体阻断细胞毒素效应物的引发并导致调节性cd8+t细胞的产生
CN111295394B (zh) 2017-08-11 2024-06-11 豪夫迈·罗氏有限公司 抗cd8抗体及其用途
WO2024097864A1 (en) * 2022-11-02 2024-05-10 Tigen Pharma Sa Expansion of lymphocytes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610878A (en) * 1983-06-16 1986-09-09 Medical University Of South Carolina Use of in vitro assay techniques to measure parameters related to clinical applications of transfer factor therapy
US4746539A (en) 1983-11-23 1988-05-24 The Ohio State University Research Foundation Purification of cancer-associated protein and preparation of antibody thereto
US4686180A (en) 1984-11-21 1987-08-11 South Alabama Medical Science Foundation Onco-fetal specific monoclonal antibodies, methods of preparation and use
US5180809A (en) 1988-05-20 1993-01-19 La Jolla Cancer Research Foundation Adhesion receptor for laminin and its use
US5525461A (en) * 1991-11-01 1996-06-11 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using total leukocyte surface antigens
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer

Also Published As

Publication number Publication date
CA2250164C (en) 2011-12-06
US6534060B1 (en) 2003-03-18
US6335174B1 (en) 2002-01-01
EP0939796A1 (de) 1999-09-08
EP0939796B1 (de) 2009-05-27
CA2250164A1 (en) 1997-10-16
DE69739423D1 (de) 2009-07-09
WO1997038089A1 (en) 1997-10-16
AU2723597A (en) 1997-10-29
EP0939796A4 (de) 2004-10-20

Similar Documents

Publication Publication Date Title
ZA91559B (en) Vaccines against cancer and infectious diseases
CA2267157A1 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
HU9302484D0 (en) Dissoluble ligands for cd-40
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
KR970704410A (ko) 암 치료용 종양 세포를 함유하는 이식 장치(Implanted Device Containing Tumor Cells for the Treatment of Cancer)
ATE306939T1 (de) Mehrstufiger kaskade-erhöhungsimpfstoff
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
ATE298367T1 (de) Interleukin-15 antagoniste
WO1998017342A3 (en) System and method for delivery of neutron beams for medical therapy
ZA90171B (en) Treatment methods and vaccines for stimulating an immune response
WO1998033527A3 (en) Cancer immunotherapy with semi-allogeneic cells
HUP0001316A3 (en) Method for the detection and localization of malignant human tumours
AU7242796A (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
ATE432339T1 (de) Verwendung von onkofötal-antigen spezifischen cd4,cd8 zytotoxischen, suppressor t-zellen und interleukin-10
ZA892275B (en) Combination therapy of il-2 and dtic for the treatment of melanoma
GB9014950D0 (en) Ehv-4 glycoprotein vaccine
EP0951475A4 (de) Impfstoff gegen metastasierenden kolorektalkrebs.
EP0202642A3 (de) Verfahren zur in vitro-Immunisierung von Humanmilzzellen gegen tumorassoziierte Antigene
GB2331460A (en) Pharmaceutical composition for the treatment of hepatitis B comprising extract of phyllanthus ussuriensis and/or phyllanthus urinaria
EP0646010A4 (de) Verwendung von müllerscher inhibierender substanz zur behandlung von tumoren und zur modulation der expression von klasse 1-haupthistokompatibilitätsantigen.
DE59712247D1 (de) Mammakarzinom-assoziiertes gen
GB8906065D0 (en) The use of monoclonal against mhc class ii determinants in therapy and vaccine strategies against hiv
DK175091D0 (da) Human tumor associated antigens, ca-ou2 and ca-ou3
AUPN918296A0 (en) Vaccines and methods for the treatment of human melanoma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties